The Myeloma Investment Fund® (MIF), a wholly owned subsidiary of the Multiple Myeloma Research Foundation® (MMRF®), drives the development of new therapies through funding, scientific expertise, and strategic guidance.
Multiple myeloma remains an incurable disease, and a challenging one to treat. There is an urgent need to develop new and novel treatment strategies to provide patients with more options to combat their disease.
This task largely falls to early-stage, venture-backed biotech companies that take on a disproportionate amount of scientific and financial risk that can only be overcome with world-class expertise and reliable funding. Investing through the MIF enables us to provide financial and strategic support to advance a robust pipeline of new myeloma therapies forward and improve the probability of their success for patients.
The MIF is uniquely positioned to identify and invest in the most promising new therapies in development – and to identify innovative technologies that could change the landscape of myeloma research. Our investments are driven by our singular goal to accelerate the development of novel therapies which could lead to cures for each and every multiple myeloma patient.
We look for companies pairing great science and a strong potential for transformative patient benefit with the potential for a significant financial return to drive the MIF’s growth and sustainability. Importantly, as a philanthropic venture fund, 100% of our financial returns are reinvested into the fund to continue supporting the development of future myeloma therapies.
If you would like to contact the Myeloma Investment Fund®, please use the email form below, call us at (203) 229 0464, or contact us by regular mail at the following address:
383 Main Avenue, 7th Floor
Norwalk, CT 06851